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Background: Nilotinib is a second-generation tyrosine kinase inhibitor that exhibits significant efficacy as first- or
second-line treatment in patients with chronic myeloid leukemia (CML). We conducted a multicenter Phase II
Clinical Trial to evaluate the safety and efficacy of nilotinib among Japanese patients with imatinib-resistant
or -intolerant CML-chronic phase (CP) or accelerated phase (AP).
Results: We analyzed 49 patients (33 imatinib-resistant and 16 imatinib-intolerant) treated with nilotinib 400 mg
twice daily. The major molecular response (MMR) rate was 47.8% at 12 months among 35 patients who did not
demonstrate an MMR at study entry. Somatic BCR-ABL1 mutations (Y253H, I418V, and exon 8/9 35-bp insertion
[35INS]) were detected in 3 patients at 12 months or upon discontinuation of nilotinib. Although 75.5% of patients
were still being treated at 12 months, nilotinib treatment was discontinued because of progressing disease in 1
patient, insufficient effect in 2, and adverse events in 9. There was no statistically significant correlation between
MMR and trough concentrations of nilotinib. Similarly, no correlation was observed between trough concentrations
and adverse events, except for pruritus and hypokalemia. Hyperbilirubinemia was frequently observed (all grades,
51.0%; grades 2–4, 29%; grades 3–4, 4.1%). Hyperbilirubinemia higher than grade 2 was significantly associated with
the uridine diphosphate glucuronosyltransferase (UGT)1A9 I399C/C genotype (P = 0.0086; Odds Ratio, 21.2; 95%
Confidence Interval 2.2–208.0).
Conclusions: Nilotinib was efficacious and well tolerated by patients with imatinib-resistant or -intolerant
CML-CP/AP. Hyperbilirubinemia may be predicted before nilotinib treatment, and may be controlled by reducing
the daily dose of nilotinib in patients with UGT1A9 polymorphisms.
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Table 1 Baseline patient characteristics
Parameters Value
Median age, y (range) 62 (19–84)
Men/women 27/22
Chronic phase/accelerated phase 45/4
Median duration of CML, months (range) 46.0 (3.6-208.2)






Cytogenetic response at baseline, Ph +%
>95/>65-95/>35-65/>0-36/0 14/6/4/2/23
BCR-ABL1 level at baseline, IS%
>10/>1-10/>0.1-1/≤0.1 18/7/10/14
Additional chromosomal abnormality, n (%) 5 (15.2)
BCR-ABL1 mutations, n (%) 6 (12.2)
CML, chronic myeloid leukemia; mo, months; TKI, tyrosine kinase inhibitor;
AraC, cytarabine; BU, busulfan; Ph +%, % of Philadelphia chromosome-positive
patients; IS%, international scale %.
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Imatinib is used as a first-line therapy for newly diag-
nosed Philadelphia chromosome-positive chronic mye-
loid leukemia (Ph + CML) [1,2]; however, some patients
fail to respond or become intolerant to this treatment
[3]. Nilotinib is a second-generation tyrosine kinase inhibi-
tor (2G-TKI) with higher selectivity and more potent in-
hibitory effects on the breakpoint cluster region-Abelson 1
(BCR-ABL1) tyrosine kinase than imatinib [4,5]. Several
studies have shown hematologic and cytogenetic responses
to nilotinib in patients with imatinib-resistant or -intolerant
CML [6-11]. Although point mutations in BCR-ABL1 are a
major cause of imatinib-resistance, nilotinib is effective in
patients with known point mutations in this oncogene, with
the exception of the T315I mutation [3]. However, the fre-
quency or profile of BCR-ABL1 point mutations has not
been determined in daily practice when treating Japanese
patients with imatinib-resistant CML in chronic phase (CP)
or accelerated phase (AP).
Hyperbilirubinemia is one of the adverse events (AEs)
caused by nilotinib. Recently, Giles et al. reported a correl-
ation between hyperbilirubinemia and nilotinib trough
concentrations in patients treated with nilotinib [12]. More-
over, nilotinib is not a substrate for uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) enzymes, but an
inhibitor of human UGT1A1 in vitro [13], and CML pa-
tients with the UGT1A1*28 polymorphism show an in-
creased risk of nilotinib-induced hyperbilirubinemia [14].
In Japanese cancer patients, UGT1A1*28, UGT1A9*1b,
UGT1A1*6 (211G > A), and UGT1A1*60 (3279 T > G) are
closely associated with the UGT1A9 IVS1 + 399 (I399C >
T) polymorphism, and linkage of I399C > T with these var-
iants has been shown to affect irinotecan metabolism [15].
However, we are not aware of any studies that have exam-
ined a correlation between hyperbilirubinemia and the
UGT1A9 I399C > T polymorphism.
The goals of the present study were as follows: 1) to
determine the major molecular response rate (MMR) at
12 months of twice daily (BID) treatment with 400 mg
nilotinib in patients with imatinib-resistant/intolerant
CML-CP or -AP; 2) to evaluate molecular responses as-
sociated with BCR-ABL1 mutation status or plasma
concentrations of nilotinib; and 3) to evaluate the safety
of administering 400 mg nilotinib BID, including hyper-
bilirubinemia development, based on plasma concentra-




Between March 13, 2009 and January 12, 2011, 51 Japanese
patients were recruited, and 49 patients (CML-CP, n = 45;
CML-AP, n = 4) were included in the study. Two patients
were excluded because they withdrew informed consent.The cut-off date for overall survival (OS) was January 11,
2013 (24 months after the last patient enrolled).
The demographic and baseline disease characteristics of
the patients are described in Table 1. The median age was
62 years. The ratio of men to women was 27:22. Thirty-
three (67.3%) and 16 (32.7%) patients were imatinib-
resistant or imatinib-intolerant, respectively. The median
duration of CML in patients was 46.0 months. The me-
dian duration of prior imatinib treatment was 43.4 months.
Patients were treated with interferon (9 patients; 18.4%)
with or without hydroxyurea (8 patients; 16.3%) prior to
imatinib therapy. Twenty-three patients (46.9%) showed a
complete cytogenetic response (CCyR), and 14 patients
(28.6%) showed MMR at the time of entry into the study.
Five patients (15.2%) had an additional chromosomal ab-
normality, and 6 patients (12.2%) had BCR-ABL1 kinase
domain mutations at baseline.Molecular response
Of the 49 patients on trial, 35 did not demonstrate an
MMR at study entry and were evaluable for response,
using the international scale of standardized quantitative
real-time polymerase chain reaction (IS-PCR). The rates
of MMR in the evaluable patients were 38.5% and 47.8%
at 6 and 12 months, respectively, and the rates of MR4.5
were 7.7% and 13.0% at 6 and 12 months, respectively
(Figure 1). The rates of BCR-ABL1 transcript levels (BCR-




































Figure 1 Molecular responses in patients with imatinib-resistant and imatinib-intolerant CML treated with nilotinib. The molecular
response was evaluated according to the international scale of standardized quantitative real-time polymerase chain reaction at the beginning of
the study and every 3 months thereafter. The X-axis shows the time-point and patient number for molecular response evaluation. The Y-axis
shows the percentage of patients who achieved a molecular response.
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33.3%, and 24.8% in patients with baselines >0.1–1%, >1–
10%, and >10%, respectively. These data represented a sig-
nificant difference between patients with baseline >0.1–1%
and those with baseline >10% (log-rank test, P = 0.0372).
The median BCR-ABL1 transcript levels (BCR-ABLIS)
reduced significantly from 10.71% to 0.14% by 12 months
in a time dependent manner (Figure 2).
BCR-ABL1 mutations and nilotinib trough concentrations
Using the direct sequencing identification method (DS), 5
BCR-ABL1 mutations (M244V, F317L, N358D, F359V, and
E459K) were detected in 6 patients (12.2%) at baseline.Figure 2 Kinetics of BCR-ABL1 expression. The black bars indicate the m
time-point and patient number for evaluation of molecular responses. The
standardized quantitative real-time polymerase chain reaction.However, M244V, N358D, and E459K were undetectable
after nilotinib treatment at 12 months. In contrast, new
somatic BCR-ABL1 mutations (Y253H, I418V, and exon
8/9 35-bp insertion [35INS]) were detected in 3 patients
(6.1%) at 12 months. These 3 patients did not achieve
MMR. The somatic BCR-ABL1 mutation (T315I) was not
detected.
Nilotinib trough plasma concentrations were mea-
sured by high-performance liquid chromatography (HPLC)
methods using blood collected at 3 months. Among 20 pa-
tients who continued treatment with nilotinib for 12 months
and did not show somatic BCR-ABL1 mutations, trough
concentrations (median, 25% to 75%) were increased inedian. The gray bars indicate quartiles 1 and 3. The X-axis shows the
Y-axis shows BCR-ABL1 transcript levels per the international scale of
Table 2 Disposition of patients at 12 months
Status N = 49
On treatment 37 (75.5%)
Treatment discontinued 12 (24.5%)
Adverse events 9 (18.4%)
Thrombocytopenia 5 (10.2%)
Hyperbilirubinemia 2 (4.1%)
Heart disease 1 (2.0%)
Headache 1 (2.0%)
No molecular response 2 (4.1%)
Disease progression 1 (2.0%)
Median actual dose intensity, mg/day (range) 651 (198–800)
Takahashi et al. Biomarker Research 2014, 2:6 Page 4 of 9
http://www.biomarkerres.org/content/2/1/6patients who achieved MMR at 12 months (774.4 ng/mL,
584.0 to 1364.0) compared to patients without MMR
(489.7 ng/mL, 317.6 to 922.5). However, the correlation be-
tween MMR at 12 months and trough concentrations of
nilotinib was not statistically significant (P = 0.261).Patient status
The disposition of patients at 12 months is summarized
in Table 2. Thirty-seven patients (75.5%) were still being
treated with nilotinib treatment, while treatment was
discontinued for 12 patients (24.5%). AEs were the most
frequent reasons for terminating treatment (9 patients;
18.4%). CML-CP progressed in 1 patient with an F317L
mutation at baseline. The median actual dose intensity
(total nilotinib dose/treatment time) was 651 mg/day.
The estimated 36-month OS was 95% in the 37 patients
on treatment and 60% in the 12 patients for which treat-
ment was terminated. These data represented a significant
difference between the two groups (Figure 3; log-rank test,
P = 0.00844).Figure 3 Overall survival of patients on present or discontinued treat
nilotinib administration to the date of death, with a minimum follow-up of
compared between groups using the stratified log-rank test. There was a sSafety
Nilotinib therapy was well tolerated. Although severe non-
hematologic AEs were infrequent, 1 patient presenting
with grade 3/4 headache and 1 with ischemic heart disease
discontinued nilotinib therapy. Grade 3/4 hematologic
AEs included anemia (14.3%), neutropenia (28.6%), and
thrombocytopenia (18.4%). Although hematologic AEs
were managed with dose interruptions or reductions, 5
patients discontinued nilotinib because of repeated or pro-
longed grade 3/4 thrombocytopenia. Although corrected
QT interval (QTc) prolongation at all grades was found in
only three patients (6.1%), grade 3/4 QTc prolongation
was not detected. QTc prolongation was also easily
managed with dose interruptions or reductions, and no
patients discontinued treatment because of this AE.
Moreover, no episodes of torsades de pointes or death
due to arrhythmias were noted. However, 1 patient dis-
continued nilotinib therapy because of ischemic heart
disease without QTc prolongation.
Grade 3/4 elevations of total bilirubin occurred in 2
patients (4.1%), and their nilotinib therapy was discontin-
ued because of repeated hyperbilirubinemia despite dose
interruptions or reductions. Although other biochemical
abnormalities were generally mild, transient, and easily
managed with dose interruptions or reductions, hyperbi-
lirubinemia was frequently observed (all grades, 51.0%;
grades 2–4, 29%). There was no statistically significant
correlation between AEs and trough concentrations of
nilotinib except for pruritus (P = 0.0440) and hypokalemia
(P = 0.0221).
The UGT1A1 and UGT1A9 polymorphisms were ana-
lyzed in all patients to identify a correlation with labora-
tory abnormalities related to liver function. Although we
did not observe a significant correlation between hyper-
bilirubinemia and UGT1A1 genotype (poor metabolizers
with UGT1A1*6/*28, *27/*28, or *28/*28 vs. extensive
metabolizers with UGT1A1 *1/*1, *1/*6, *1/*27, or *1/*28),ment after 12 months. OS was measured from the date of initial
24 months. OS was estimated using the Kaplan-Meier method and
ignificant difference between the 2 groups (log-rank test, P = 0.00844).
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I399C/C genotype (P = 0.028) (Table 3). This genotype
was observed in 33% of patients with hyperbilirubinemia
higher than grade 2. The UGT1A9 I399C/C genotype was
a statistically independent factor according to the results
of stepwise forward selection multiple regression analysis
(P = 0.0086, Odds Ratio, 21.2; 95% Confidence Interval,
2.2–208.0).
Discussion
The present study revealed that nilotinib therapy was ef-
fective in Japanese patients with CML-CP/AP who have
developed imatinib resistance or intolerance. Approxi-
mately 50% of the patients in this Phase II trial achieved
MMR, and the estimated OS at 36 months for patients
on treatment was 95%. Responses were more likely in
patients with BCR-ABLIS ≤1% at baseline than in those
with BCR-ABLIS >1%. In a phase II trial of nilotinib for
imatinib resistance or intolerance reported by Kantarjian
et al. [9], MMR was achieved in 32% (43 of 134) of pa-
tients at 12 months. The lower MMR reported in that
study as compared to the rate observed in the present
study might be explained by differences in response at
baseline. The CCyR at baseline observed by Kantarjian
et al. [9] was 3%; in comparison, 26% (9 of 35 patients)
showed this response in our trial. In the Expanding Nilo-
tinib Access in Clinical Trials (ENACT), the molecular
responses in a subset of French patients (n = 168) every
3 months were evaluated. Thirty-seven percent achieved
MMR, and 20% achieved MR4.5 by 12 months [10]. In
a phase I/II study of nilotinib treatment of Japanese
patients with imatinib-resistant or -intolerant CML or
relapsed/refractory Ph + acute lymphoblastic leukemia
(ALL), 16 patients with CML-CP were assessed using IS-
PCR to detect molecular responses every 3 months [6].
The level of BCR-ABL transcription gradually decreased
from baseline, with a 1-log reduction at 6 months and a 2-
log reduction at 12 months. Our findings are consistentTable 3 Liver dysfunction and UGT1A1/1A9 polymorphisms
Liver test Grades 2-4 UGT1A1
Poor metabolizers Extensive meta
ALT No 3 41
Yes 1 4
AST No 3 44
Yes 1 1
T.Bil No 1 35
Yes 3 10
Nilotinib C0 Median 687.6 1042.0
Range (25–75) (336.1-1906.6) (614.9-147
Poor metabolizers, UGT1A1 *6/*28, *27/*28, or *28/*28; Extensive metabolizers, UGTwith these observations and suggest that nilotinib is highly
active in patients with imatinib-resistant or -intolerant
CML-CP/AP.
We detected 5 BCR-ABL mutations (M244V, F317L,
N358D, F359V, and E459K) in 6 patients at baseline
screening. Among these patients, M244V, N358D, and
E459K were not detected after nilotinib treatment at
12 months, and 3 patients with these mutations achieved
MMR. In contrast, patients with F317L and F359V +
E459K mutations showed poor responses to nilotinib
treatment, and 1 patient with F317L experienced disease
progression. The remaining patient with F359V + E459K
mutations did not respond to nilotinib, and treatment was
discontinued because of grade 3 thrombocytopenia. A pre-
vious study showed that patients with F317L or F359V
mutations are resistant to nilotinib [16,17]. The present
study also suggests that these mutations at baseline may
be associated with less favorable responses to nilotinib.
We detected 3 new mutations in 3 patients after they
started nilotinib treatment (Y253H, I418V, and exon 8/9
35-bp insertion). Although the Y253H mutation was less
sensitive to nilotinib in an in vitro cell viability assay
(IC50 > 150 nM) [17], the level of BCR-ABL1 transcripts
in the Y253H patient in our trial decreased from 8.06%
to 0.30%. Qin et al. [18] reported the I418V mutation in
a Chinese patient who progressed to blast phase while
on imatinib therapy. Although a patient with the somatic
I418V mutation in our trial was in second chronic phase
at baseline, the disease did not progress. However, the
levels of the BCR-ABL1 transcript were maintained from
59.36% at baseline to 50.21% at 12 months. Another rare
mutation of BCR-ABL1 is 35INS, which is a 35-bp inser-
tion between ABL kinase domain exons 8 and 9 [19].
This insertion results in a frameshift, leading to the
addition of 10 residues and truncation of 653C-terminal
residues due to early termination [20]. One patient with
35INS in our trial showed a mild reduction in the level
of BCR-ABL1 transcripts from 10.71% at baseline to 2.89%UGT1A9 I399C > T
bolizers P-value C/T + T/T C/C P-value
0.359 39 4 0.111
3 2
0.158 41 5 0.237
1 1
0.052 34 2 0.028
8 4
0.577 977.5 644.0 0.685
2.8) (544.0-1473.0) (623.0-2292.0)
1A1 *1/*1, *1/*6, *1/*27, or *1/*28; C0, trough concentration.
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inactive and does not contribute to TKI resistance [21].
Patients who did not achieve MMR and harbored somatic
mutations showed relatively poor responses to nilotinib.
However, a mutation (e.g. 35INS) might not be causally
related, suggesting the possibility of genomic instability,
and that other genetic abnormalities might contribute to
TKI resistance. Conversely, the T315I mutation, which is
known to cause resistance to imatinib and nilotinib, was
not detected in the present study.
In the Evaluating Nilotinib Efficacy and Safety in Clin-
ical Trials-newly diagnosed (ENESTnd) patients, the
occurrence of all-grade total bilirubin elevation was sig-
nificantly higher in patients with higher nilotinib expos-
ure [22]. Although we could not identify a correlation
between nilotinib trough concentrations and hyperbilir-
ubinemia in the present study, nilotinib trough concen-
tration has been associated with the occurrence of
all-grade elevations in total bilirubin [12]. However, to
our knowledge this is the first report of a significant
correlation between hyperbilirubinemia and the UGT1A9
I399C/C genotype.
UGT1A1 catalyzes gluconidation of hepatic bilirubin
in humans [23]. The presence of 7-TA nucleotide re-
peats in the (TA)nTAA promoter region of UGT1A1
(UGT1A1*28) leads to decreased expression of this gene,
resulting in high plasma bilirubin levels that form the
basis for Gilbert’s syndrome [24]. Because nilotinib is a
potent noncompetitive inhibitor of human UGT1A1 activ-
ity [13], the UGT1A1*28 polymorphism increases the risk
of nilotinib induced-hyperbilirubinemia [14,25]. These ob-
servations suggest that nilotinib-associated hyperbilirubi-
nemia is very likely the result of inhibition of UGT1A1
activity, combined with genetic defects in UGT1A1. Al-
though, UGT1A9 is also an enzyme of the glucuronida-
tion pathway that transforms small lipophilic molecules,
such as steroids, bilirubin, hormones, and drugs, into
water-soluble, excretable metabolites, we are not aware
of any reports indicating that nilotinib-induced hyperbi-
lirubinemia is related to the UGT1A9 I399C/C geno-
type. It has been shown that the enzyme function of the
UGT1A9 I399C > T genotype does not contribute to
variability in UGT1A9 activity [26]. On the other hand,
Saito et al. reported the role of UGT1A9 I399C > T in
SN-38 glucuronidation in a study of 177 Japanese can-
cer patients administered irinotecan. Haplotype analysis
showed that 98% of UGT1A9 I399C alleles was linked to
low-activity genotypes, either UGT1A1*6, *28, or *60
[15]. Our study suggests that hyperbilirubinemia is
associated with the UGT1A9 I399C/C genotype. For
Japanese patients with CML, hyperbilirubinemia may be
predicted before nilotinib treatment and controlled by
reducing the daily dose of nilotinib in patients with
UGT1A9 polymorphisms.Conclusions
The results of our study suggest that nilotinib is generally
well tolerated by patients and effectively treats imatinib-
resistant or -intolerant CML-CP/AP.
Methods
Eligibility criteria
Twenty-seven institutions in the East Japan CML study
group (EJCML) participated. Patients with Ph + CML-
CP/AP who were at least 18 years of age were eligible if
they were imatinib-resistant or -intolerant, demonstrated
adequate performance status (World Health Organization
[WHO] Performance Score [PS] <2), and had normal hep-
atic, renal, and cardiac functions. Patients were excluded if
they exhibited any of the following characteristics: blast
phase, QTc >450 ms, and the T315I mutation. Imatinib
resistance was defined as an incomplete hematologic re-
sponse at or after 3 months, no MCyR at 6 months, no
CCyR at 12 months, or no MMR at 18 months, according
to the criteria of failure and suboptimal response of Euro-
pean LeukemiaNet [3]. Imatinib intolerance was defined
as a lack of optimal response because of a grade 3/4
imatinib-related AE, or because of a persistent grade 2
imatinib-related AE, despite optimal supportive care, that
persisted for more than 1 month or recurred more than 3
times following reduction of the dose of imatinib.
Clinical trial design and objectives
The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki. Informed consent
was written by all patients according to institutional
guidelines. The study was approved by all institutional
review boards and registered with ClinicalTrials.gov
(number UMIN000002201). The primary objective of
this phase II, single-treatment arm, open-label study
was to determine the incidence of MMR at 12 months
in patients with imatinib-resistant/intolerant CML-CP/
AP who were treated with nilotinib. The molecular re-
sponse was evaluated according to IS-PCR upon study
entry and every 3 months thereafter. Secondary objectives
were to evaluate the relationship between the molecular
response and BCR-ABL1 point mutations or plasma con-
centrations of nilotinib, and between the safety profile of
nilotinib and plasma concentrations of the drug and or
UGT 1A1/1A9 polymorphisms.
Dosing regimen and concomitant therapy
Nilotinib was administered orally at 400 mg BID, at ap-
proximately 12-h intervals. Food was not consumed with
the drug, or for at least 2 h before and 1 h after the drug
was ingested. The concomitant administration of a strong
inhibitor, including grapefruit juice, or inducer of CYP3A,
was not allowed in the study.
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IS-PCR was performed in a central laboratory (BML Inc.,
Kawagoe, Japan) using the MolecularMD One-Step qRT-
PCR BCR-ABL kit (MolecularMD, Cambridge, MA). An
MMR was defined as a 3-log reduction in the level of the
BCR-ABL1 transcript using IS-PCR (BCR-ABLIS 0.0032–
0.1%). At least 10,000 control genes (ABL1) were required
for a sample to be classified as adequate. MR4.5 was de-
fined as ≥4.5-log reduction in the levels of the BCR-ABL1
transcript (BCR-ABLIS ≤0.0032%) in peripheral blood
samples, and at least 32,000 control genes were required
for a sample to be classified as adequate. Patients with
MMR at baseline were considered not eligible and were
excluded from the analysis of response rates.
Measurement of nilotinib concentration and Genotyping
Nilotinib trough concentrations (C0) were determined
using HPLC as described previously [27]. BCR-ABL1 mu-
tations were analyzed by the DS method as previously de-
scribed [28]. Genotyping of UGT1A1*6, *27 and *28 was
performed using PCR-restriction fragment length poly-
morphism as described [29,30]. The analysis results ob-
tained from PCR-RFLP were confirmed using a fully
automated single nucleotide polymorphism (SNP) detec-
tion system (prototype i-densy™, ARKRAY Inc., Kyoto,
Japan). The UGT1A9 I399C > T (relative to the end of
UGT1A9 exon 1) polymorphism was genotyped by dir-
ect sequencing using a PCR procedure as previously
described [31]. All genotype frequencies were tested for
their consistency with Hardy-Weinberg equilibrium.
Safety analyses
Safety was assessed by determining the frequency and
severity of AEs, which included hematologic and bio-
chemical laboratory tests, vital signs, physical examina-
tions (including body weight), WHO PS cardiac function
tests (12-lead electrocardiogram, cardiac enzyme test,
and echocardiography), and chest X-rays. AEs were
graded according to the National Cancer Institute Com-
mon Terminology Criteria for AEs (version 3.0).
Statistical analyses
Statistical analyses were performed using SPSS statistical
software (version 17.0, SPSS Japan Inc., Tokyo, Japan).
Data were presented as number or median values (range
or 25% to 75%). Differences in the various parameters be-
tween groups were evaluated using the Mann–Whitney U
or chi-square tests. Time to MMR was measured from the
date of initial nilotinib administration to the date of MMR
during the study. OS was measured from the date of initial
nilotinib administration to the date of death with a mini-
mum follow-up of 24 months. OS and the cumulative in-
cidence of MMR were estimated using the Kaplan-Meier
method and compared between groups using the stratifiedlog-rank test. Stepwise forward selection multiple regres-
sion analysis was performed to determine the effect of the
variables examined in univariate analysis. A P value
of <0.05 was considered significant.
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